Key result
Sacubitril/valsartan linked to ~2-point improvement in RV free wall longitudinal strain in HFrEF.
Why the study?
Sacubitril/valsartan improves LV function in HFrEF, but whether it also improves impaired RV function and what predicts this improvement remained unknown.
Does sacubitril/valsartan improve right ventricular function in patients with chronic HFrEF?
Observational (n=50)
Single-blind (echocardiographic studies interpreted by physicians blinded to clinical data)
No
Does sacubitril/valsartan improve right ventricular function in patients with chronic HFrEF?
In patients with HFrEF, 6 months of sacubitril/valsartan therapy is associated with significant improvements in right ventricular function, which can be predicted by baseline RV S' and right atrial volume.
Answers are grounded in this paper and cite their sources.
May inform RV monitoring during sacubitril/valsartan use in HFrEF; hypothesis-generating pending randomized confirmation.
BACKGROUND: Observational studies have demonstrated that treatment with sacubitril/valsartan may improve left ventricular (LV) systolic and diastolic function in subjects with reduced LV ejection fraction (LVEF) in real-world studies. Subjects with heart failure and reduced EF (HFrEF), however, are also characterized by an impaired right ventricular (RV) function. We therefore aimed to evaluate whether also RV function may improve after S/V therapy and possible predictors of RV improvement could be identified at echocardiography and tissue Doppler imaging. METHODS: Fifty consecutive patients (67 ± 8 years, LVEF 28 ± 6%, male 86%) with chronic HFrEF and NYHA class II-III were followed up for 6 months after therapy with S/V. LV&RV function was assessed at baseline and after 6 months of therapy. RESULTS: After 6-month therapy with S/V a significant improvement was shown in the following echocardiography parameters assessing RV function: PAsP (31 ± 11 vs. 35 ± 10 mmHg, p < 0.001), TAPSE (19 ± 3 vs. 18 ± 3 mm, p < 0.001), RV FAC (38 ± 7 vs. 34 ± 6 mm, p < 0.001), RV S' (12 ± 2 vs. 10 ± 2 cm/s, p < 0.001), RV-FW-LS (-20 ± 5 vs. -18 ± 5%, p < 0.001), RV-4Ch-LS (-16 ± 5 vs. -14 ± 5%, p < 0.001). At multivariable analysis improvement in RV-FW-LS was associated to baseline levels of RV S' (r 0.75, p < 0.01) and RAV (r -0.32, p < 0.05). CONCLUSIONS: In a real-world scenario, 6-month therapy with S/V was associated with an improved RV function in HFrEF. RV function improvement may be predicted by assessing baseline RV S' and right atrial volume values.
No takes yet. Share an insight, caveat, or question.
Correale et al. (2021) conducted an observational in Chronic heart failure with reduced ejection fraction (HFrEF) (n=50). Sacubitril/valsartan vs. Baseline (pre-treatment values in a paired before-and-after analysis) was evaluated on Right ventricular free wall longitudinal strain (RV-FW-LS, %) (p=<0.001). Sacubitril/valsartan therapy for 6 months improved right ventricular free wall longitudinal strain and TAPSE in patients with HFrEF.
Synapse has enriched 10 related papers. Consider them for comparative context: